Shattuck Labs, Inc. (STTK)
STTK Chart as of 2025-04-07
Stock Information
| CEO: | – |
| CFO: | – |
| Employees: | 44 |
| Address: | 500 West 5th Street, Austin, TX, United States |
| Country: | United States |
| Website: | https://www.shattucklabs.com |
| Listing Date: | – |
| Founded: | – |
| Founder: | – |
| Current Price: | 1.2999999523162842 USD |
| Today Change: | 82.84% |
| Outstanding Shares: | 47,899,200 |
| Volume: | 3,282,499 |
| Avg Volume: | 148,153 |
| Expert Target Price: | 2.6000 (Institutions: 0) |
| EPS: | – |
| PER: | – |
| Dividend Date: | – |
| Last Split Date: | – |
| Last Split Factor: | – |
Key Executives
| Name | Title | Pay | Year |
|---|---|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, CEO & Director | 792.88k | — |
| Mr. Andrew R. Neill M.B.A. | Chief Financial Officer | 603.96k | — |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer | 695.24k | — |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer | 567.4k | — |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | — | — |
| Ms. Casi DeYoung | Chief Business Officer | 523.48k | — |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs | — | — |
| Mr. George Fromm Ph.D. | Co-Chief Scientific Officer | — | — |
| Mr. Suresh de Silva Ph.D. | Co-Chief Scientific Officer | — | — |
| Ms. Kelli Collin M.S. | Senior Vice President of Quality | — | — |
Financials
Income Statement
| Metric | Amount |
|---|---|
| Total Revenue | 5,721,000 |
| Cost Of Revenue | – |
| Gross Profit | – |
| Operating Income | -80,567,000 |
| Net Income | -75,410,000 |
Balance Sheet
| Metric | Amount |
|---|---|
| Total Assets | 91,049,000 |
| Total Liabilities | – |
| Total Stockholder Equity | – |
Cash Flow
| Metric | Amount |
|---|---|
| Total Cash From Operating Activities | – |
| Capital Expenditures | – |
SEC Filings (Gemini Summaries)
| AccNo | Date | Summary |
|---|---|---|
| 0001193125-25-064686 | 2025-03-27 | Amendment to prospectus (7/29/22) reduces common stock offering to $24.4M due to SEC rules limiting sales based on public float (now below $75M). No shares sold previously. STTK stock listed on Nasdaq. |
| 0001193125-25-064683 | 2025-03-27 | Shattuck Labs, Inc. filed an S-8 form on March 27, 2025, registering 1,908,588 shares for its 2020 Equity Incentive Plan. Previous filings are incorporated by reference. Taylor Schreiber, CEO, signed the filing. |
| 0001680367-25-000012 | 2025-03-27 | STTK (Shattuck Labs) SEC filing for FY 2024 (ending Dec 31). Includes financial data, stock info, assets, liabilities, collaborative arrangements (ImmunoGen), license agreements (Ono), and stock incentive plans. |
| 0001680367-25-000009 | 2025-03-27 | Shattuck Labs (STTK) filed an 8-K on 03/27/25, reporting financial results for the year ended 12/31/24 via press release (Exhibit 99.1). They are an emerging growth company. |
| 0000902664-25-000863 | 2025-02-12 | This SEC filing text defines CSS styles for a website, specifying formatting for text boxes and table elements (borders, fonts, colors, alignment, etc.). |
News Summary
– Palkansaajat ja työnantajat eri linjoilla henkilöstön hallintoedustuksen muutostarpeista
2025-04-01 09:11:49 | YLE News
Uutiset nopeasti ja luotettavasti.
Link
– Työryhmä ehdottaa keinoja raskaussyrjinnän kitkemiseksi – Ei riitä, arvioivat palkansaajat
2025-03-18 07:00:41 | YLE News
Työryhmä vahvistaisi määräaikaisen työntekijän asemaa siten, ettei häntä saisi asettaa eriarvoiseen asemaan esimerkiksi raskauden tai synnytyksen vuoksi.
Link
– Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Leerink Partners
2025-03-18 05:54:47 | ETF Daily News
Leerink Partners assumed coverage on shares of Shattuck Labs (NASDAQ:STTK – Free Report) in a research note released on Monday. The brokerage issued an outperform rating and a $4.00 price target on the stock.
Link
– Ylen tiedot: Kiistelty palkka-avoimuus taas myöhässä – viimeksi Marinin hallitus sai haukut saamattomuudesta
2025-03-31 16:05:19 | YLE News
EU:n palkka-avoimuusdirektiivi pitää saada ensi vuoden kesään mennessä täytäntöön. Aiemmat työryhmät ovat epäonnistuneet, nyt on pakko edessä.
Link
– EK:n johtaja kertoo Työeläke-lehdessä, miten eläkesopu syntyi – “Enää ei katsota, kenen vatsa kestää parhaiten kahvia”
2025-03-17 08:39:00 | Www.is.fi
Eläkeuudistuksen ratkaisijana toiminut EK:n johtaja Ilkka Oksala arvioi Työeläke-lehdessä, että sijoitusuudistus ei yksin riitä.
Link
Analysis of Today’s Move
**Shattuck Labs (STTK) Stock Rally Analysis**
Shattuck Labs (STTK) experienced a notable rally today, driven by a combination of factors. A key catalyst appears to be the initiation of coverage by Leerink Partners. The brokerage firm issued an “outperform” rating. Their price target of $4.00 further fueled investor optimism. This positive analyst sentiment likely attracted increased buying pressure.
The Leerink Partners coverage directly influences investor perception. Their “outperform” rating suggests confidence in Shattuck Labs’ future prospects. This signals a positive outlook, potentially validating the company’s strategic direction. Such endorsements often lead to increased trading volume and stock price appreciation. It’s important to note the target price.
Recent SEC filings also provide insight into the company’s activities. The filing of an S-8 form registering shares for the 2020 Equity Incentive Plan is notable. This action often signals ongoing commitment to employee retention. It demonstrates the use of equity incentives. This is a common practice in emerging growth companies like Shattuck Labs.
The company’s FY2024 filing reveals crucial financial details. Key highlights likely include financial data and collaborative arrangements. Their collaborations with ImmunoGen and license agreements with Ono are significant. These partnerships can impact the company’s revenue streams and development pipeline. The 8-K filing reporting financial results further reinforces this point.
Finally, the amended prospectus reduces the common stock offering. This was due to SEC rules related to the public float. This change could be interpreted as a positive sign by some investors. It may indicate that the company is managing its capital effectively. This event coincides with positive analyst sentiment.
This stock has shown a change of 82.84% today.
Please consider that all investment decisions carry risk;
none of the content here should be construed as financial advice.
Always do your own research or consult a professional before making investment decisions.
The information provided in this article is for informational purposes only
and does not constitute legal, tax, or investment advice.
Investing involves risk, including the potential loss of principal.
Leave a Reply